gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · MISTHealthcarePharmaceuticals

Milestone Pharmaceuticals Inc. Common Shares (MIST)

$0.7725+1.74%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$0.77▼ 58.02% in range
Nov 4, 2025Low $0.64 · High $2.95Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Milestone Pharmaceuticals Inc. Common Shares closed at $0.77 on Nov 4, up 1.74%, 73.8% below its 52-week closing high. Volume of 696.0K shares was 0.77× its 20-day average (below normal).

Split-adjusted performance: +1.1% over one month, -60.8% over six months, -58.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $559K, with a net margin of -5118.8%.

Short interest was 19.7M shares at the Oct 15 settlement, up 3.7% from the prior report (17.9% of float, 18.7 days to cover).

Market cap$96.2M124.5M shares
Revenue · quarter$559.0K—
Diluted EPS$-0.21—
P/E · TTM—P/S 41.0×
Net margin-5,118.8%Gross 94.3%
Dividend yieldNone
52-week range0.64 – 2.95−73.8% from high
Volume696.0K0.77× 20-day avg
Volatility · 60d74.2%Annualised
Short % of float17.9%18.7 days to cover
Net cash$111.4MCash $170.6M
Next earnings—Not scheduled
Split-adjusted performance
1W +2.0%1M +1.1%3M −34.5%6M −60.8%YTD −61.8%1Y −58.2%3Y −67.5%5Y −86.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum18
Revenue growth—
Net margin8
Value (low P/E)—
Size40

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short19.7M+3.7% vs prior
Days to cover18.7Settled Oct 15
% of float17.9%
Short vol. 10d51.2%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
MISTMilestone Pharmaceuticals$0.7725+1.74%−60.8%—−5118.8%—$96.2M
VTVTvTv Therapeutics$24.03+2.04%−24.1%———$95.0MCompare
PDSBPDS Biotechnology$1.30−7.80%+22.6%———$94.2MCompare
CATXPerspective Therapeutics$0.8702−1.11%−77.2%−72.1%−33069.1%—$99.3MCompare
NTHINeOnc Technologies Holdings$3.17+3.26%−40.3%———$91.3MCompare
PLYXPolaryx Therapeutics$1.80+4.05%−52.6%———$89.7MCompare
GNLXGenelux$1.96+2.08%−31.7%———$88.7MCompare
UNCYUnicycive Therapeutics$3.75+4.46%−53.9%———$104.5MCompare
OKUROnKure Therapeutics$2.59+3.60%−36.4%———$104.9MCompare

News about Milestone Pharmaceuticals

All news →
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. · 1d agoNeutralMilestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVTGlobeNewswire Inc. · Apr 10, 2026▲ Positive

Quick answers

What does Milestone Pharmaceuticals Inc. Common Shares do?
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs.
What is MIST's market cap?
$96.17M, based on the Nov 4 close of $0.77.
Does Milestone Pharmaceuticals Inc. Common Shares pay a dividend?
No regular cash dividend has been paid in the last year.
How much of MIST is sold short?
19.7M shares, 17.9% of float, as of Oct 15, 2026.
What sector is MIST in?
Healthcare, in the Pharmaceuticals industry.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.

HQ: Montreal, A838 employeesListed May 9, 2019milestonepharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology